Emerging Data and Best Practices for the Use of Novel Therapies in Endometrial Cancer: Managed Care Considerations in an Evolving Treatment Paradigm

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive from the live session from the 2023 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from June 1, 2023 to August 1, 2024

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from

Cancer of the uterine corpus, also called endometrial cancer (EC), is the most common cancer of the female genital tract, with an estimated 65,950 new cases diagnosed and 12,550 deaths annually in the United States. The mortality rate has increased approximately 1% each year from 2015 to 2019, an increase which may be related to a higher rate of advanced-stage cancers, high-risk histologies, and patients being diagnosed at an older age. There are significant disparities between White and Black women regarding rates of early-stage diagnosis (75% vs 62%) and 5-year relative survival (84% vs 63%). When patients are diagnosed with distant-stage disease, 5-year relative survival rates plummet to 18% for all races. Early identification of high-risk patients and personalized treatment approaches for this complex, multifaceted disease are needed to improve outcomes. Fortunately for patients with endometrial cancer, new and emerging combination regimens, including immunotherapy and targeted therapy combinations, have been approved in recent years, giving managed care professionals and clinicians more options for treating this patient population. With so many new therapies entering the treatment paradigm, knowledge gaps have been created, making it imperative that managed care physician medical directors, oncologists, pharmacists, payers, nurses and other healthcare professionals who manage EC patient populations have a solid understanding of these options to optimize both costs and patient outcomes in their therapeutic application, for optimized clinical and economic outcomes.

Upon completion of this activity, participants will be able to:

  • Assess the clinical and economic burden of endometrial cancer (EC) in terms of relative survival, mortality, drug utilization, adverse event management, and hospitalizations

  • Explore the prognosis of advanced endometrial cancer and the significance of biomarkers in determining appropriate therapy

  • Analyze recent clinical data on the efficacy, safety and mechanisms of action of novel therapies, including PD-1 inhibitors, in the management of endometrial cancer

  • Review the guideline-recommended role of immune-based therapies in the management of endometrial cancer

  • Investigate health equity issues affecting patients with endometrial cancer and the potential impact of disparities on clinical outcomes

  • Discuss access to care, cost of care, and cost-effectiveness of immune checkpoint inhibitors in the treatment of endometrial cancer


Faculty: Shannon N. Westin, MD, MPH
Medical Director, Gynecologic Oncology Center
Director, Early Drug Development
Dept. of Gynecologic Oncology and Reproductive Medicine
UT MD Anderson Cancer Center


(Relevant Financial Relationships with Ineligible Companies in the Last 24 Months):
Dr. Westin has served as a consultant for AstraZeneca, Caris, Clovis Oncology, Eisai, EQRX, GSK, ImmunoGen, Lilly, Merck, Mereo, Mersana, NGM Bio, Nuvectis, Roche/Genentech, SeaGen, Verastem, Vincerx, and Zentalis. She has received grant/research support from AstraZeneca, AvengeBio, Bayer, Bio-Path, Clovis Oncology, GSK, Mereo, Novartis, Roche/Genentech, and Zentalis. Her presentation has been reviewed for any bias.
Planning Committee: Bill Williams, MD has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

Jeremy Williams has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by an educational grant from

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue